ESCRS - OSD in glaucoma patients ;
ESCRS - OSD in glaucoma patients ;

OSD in glaucoma patients

OSD in glaucoma patients
Cheryl Guttman Krader
Cheryl Guttman Krader
Published: Saturday, September 22, 2018
GLAUCOMA is not just an optic neuropathy – it is also an ocular surface disease (OSD), said Florent Aptel MD, PhD. Speaking at the 9th EuCornea Congress, Dr Aptel discussed OSD prevalence among patients with glaucoma and reviewed the etiology, diagnosis and management of OSD. Results of several studies document that OSD is very common in glaucoma patients and show that it is related to the burden of use of medications containing preservatives. For example, one study found that more than half of glaucoma patients using two or three medications containing preservatives had signs or symptoms of OSD. Findings from epidemiologic studies and basic science research establish benzalkonium chloride (BAK) as the primary culprit in medication-related OSD toxicity. “Therefore, it is likely better to avoid glaucoma medications preserved with BAK, especially in patients with OSD as well as in patients who are on multidrug regimens or who will have future filtering surgery,” said Dr Aptel, professor of ophthalmology, University Hospital of Grenoble, Grenoble, France. “Fortunately, there are several preservative-free glaucoma medications available now in both monotherapy and fixed combination options. Results of comparative studies show no differences in the IOP-lowering activity of preservative-containing and preservative-free formulations of the same active ingredient.” Identifying the presence of OSD in patients with glaucoma should begin with a good history. “It is very important to remember that in most patients, the symptoms of OSD precede the physical abnormalities,” Dr Aptel said. Slit-lamp examination and fluorescein staining are generally adequate to assess for signs of OSD.
Tags: cornea, glaucoma, osd
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular

Long-awaited cellular therapies for corneal endothelial disease enter the clinic.

Read more...

Balancing Innovation and Safety

Ensuring access to advanced cell therapies amid regulatory overhaul.

Read more...

With Eyes on Its Future, ESCRS Celebrates Its Past

Winter Meeting offers opportunities to experiment with new concepts and formats.

Read more...

Best of ESCRS Winter Meeting 2024

Read more...

Following the New Generation

EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.

Read more...

Refocus on Multifocals

Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.

Read more...

Common Myths in Presbyopia Correction

Patient education key to satisfaction with refractive IOLs.

Read more...

Reversible Multifocality

Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.

Read more...

Managing a Cataract Surgery Refractive Miss

Weighing the pros and cons of options for intraocular intervention.

Read more...

Unleashing OCT’s Full Potential

Performance of newest tool for corneal evaluation meets or beats older standard technologies.

Read more...

;